Halpern gclam
WebDec 12, 2024 · Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival M-EM, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms ... WebMar 6, 2024 · A multivariable analysis controlling for baseline prognostic features showed that the mitoxantrone dose of 16 mg/m 2 per day was associated with significantly better overall survival, compared with a dose of 10 mg/m 2 per day used in a historical cohort according to standard GCLAM dosing (hazard ratio for death, 0.45).
Halpern gclam
Did you know?
WebAnna B. Halpern from Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA, and colleagues conducted a phase … WebDownload Table Comparison of baseline study characteristics across induction regimens from publication: Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other ...
WebSep 30, 2016 · Palmieri R, Buckley SA, Othus M, Halpern AB, Percival MM, Scott BL, Hendrie PC, Becker PS, Oehler VG, Estey EH, Walter RB. Randomized phase 1 study of … WebJan 24, 2014 · PRIMARY OBJECTIVES: I. Estimate the maximum tolerated dose (MTD) of dose-intensified mitoxantrone hydrochloride (mitoxantrone) as part of the filgrastim (G-CSF), cladribine, cytarabine, mitoxantrone hydrochloride (G-CLAM) regimen separately for adults with newly diagnosed acute myeloid leukemia (AML) and those with relapsed/refractory …
WebOct 11, 2024 · GCLAM differs from FLAG-Ida in the use of mitoxantrone rather than idarubicin and, primarily, in the substitution of cladribine for fludarabine. ... Halpern AB, … WebNational Center for Biotechnology Information
WebWe retrospectively identified adults over 18 years with newly diagnosed WHO-defined AML/high grade myeloid neoplasms (>10% blasts) who received high intensity induction chemotherapy (cladribine, cytarabine, mitoxantrone, and G-CSF, also known as CLAG-M or GCLAM) between 5/1/2014 and 12/31/2024. Patients with variations to the CLAG-M …
WebDec 10, 2024 · Dr Halpern speaks with ecancer at the 2024 ASH annual meeting about the final results from the phase 1/2 trial looking at G-CSF, cladribine, cytarabine, and dose-escalated mitoxantrone (GCLAM) in adults with relapsed/refractory acute myeloid leukaemia or high-grade myeloid neoplasms. thea farma contattiWebThe safety of GCLAM using mitoxantrone at 10mg/m2/day on days 1–3 in relapsed/ refractory AML is well-established.11 Therefore, in phase 1, patients were assigned to … the frighteners 1996 plotWebOct 4, 2024 · Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. 17 April 2024. Anna B. Halpern, Megan Othus, … Roland B. Walter. the frighteners 4k uhdWebMar 6, 2024 · GCLAM therapy shows promise for relapsed/refractory AML. Publish date: March 6, 2024. By Sharon Worcester ... the frighteners 1996 trailerWebOct 11, 2024 · GCLAM differs from FLAG-Ida in the use of mitoxantrone rather than idarubicin and, primarily, in the substitution of cladribine for fludarabine. ... Halpern AB, Othus M, Huebner EM, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. … the frighteners 1996 streamingWebMar 6, 2024 · Of 40 patients who were treated with GCLAM (with mitoxantrone at the maximum tolerated dose of 16 mg/m 2 per day as established in phase 1 of the trial), 11 … the frighteners 1996 posterWebThe Laughing Clam, Grants Pass, Oregon, Grants Pass. 4,285 likes · 12 talking about this · 16,331 were here. A Pacific NW Alehouse & Eatery located in the heart of historic downtown Grants Pass. the a factor